RedGage is the best way to earn real money from your photos, videos, blogs, and links.

View the Video Sign Up

Celgene craters 16% after slashing its forecast for 2 key drugs (CELG)
  • Next
  • Previous

    • Celgene craters 16% after slashing its forecast for 2 key drugs (CELG)
    Celgene craters 16% after slashing its forecast for 2 key drugs (CELG)
    Celgene was hurt by weaker-than-expected sales of its flagship multiple myeloma drug Revlimid and psoriasis drug Otezla.
    Source: www.businessinsider.com
    Thanks. Your rating has been saved.
    You've added this content to your favorites.
    Load More
    ronstew
    Edit Show Details
    0 0 0
    Description

    Celgene was hurt by weaker-than-expected sales of its flagship multiple myeloma drug Revlimid and psoriasis drug Otezla.

    Tags
    $0.00
    Make money on RedGage just like ronstew!
    Load More
    Flag This Content